Ripretinib 50 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 50 mg

Reference Brands: Qinlock (USA/EU)

Category: Oncology Cancer Care

Ripretinib is a Oncology Cancer Care product available as Tablets in strengths 50 mg. It corresponds to the reference brand Qinlock (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Ripretinib, marketed under the brand name Qinlock®, is an orally administered targeted anticancer medication approved for the treatment of adults with advanced gastrointestinal stromal tumor (GIST). GIST is a rare type of cancer that originates in the gastrointestinal tract and is commonly driven by activating mutations in the receptor tyrosine kinases KIT or platelet-derived growth factor receptor alpha (PDGFRA). Ripretinib is indicated as a fourth-line therapy for patients whose disease has progressed after prior treatment with multiple kinase inhibitors.

Ripretinib is a small-molecule inhibitor designed to broadly suppress KIT and PDGFRA signaling. Its unique dual mechanism of action enables it to inhibit a wide range of primary and secondary mutations that commonly develop after successive treatment lines, contributing to drug resistance. This broad mutation coverage makes ripretinib an important option for heavily pretreated patients.

The clinical benefit of ripretinib was demonstrated in the pivotal phase III INVICTUS trial, which showed a significant improvement in progression-free survival compared with placebo. Efficacy was observed across multiple KIT mutation subtypes, including exon 9, 11, 13, and 17. Ripretinib has an acceptable tolerability profile, with common severe adverse events including lipase elevation, hypertension, fatigue, and hypophosphataemia, supporting its role as a valuable therapy in advanced GIST management.